Juranić Z, Stanojević-Bakić N, Maletić V, Borkovacki R
Institute of Oncology and Radiology, Belgrade, Yugoslavia.
Neoplasma. 1994;41(4):229-32.
Immunoreactive proteins--serum immunoglobulins and immune complexes were evaluated in renal cell carcinoma (RCC) patients. The analyses were done after radical nephrectomy before, at the end, and six months after the therapy, with IFN alpha alone (in patients in Stage II) or IFN alpha in the combination with vinblastine (in patients in Stage III and IV of the disease). Data obtained before immuno- or immunochemotherapy show significant increase in IgG and IgA concentrations in RCC patients in all stages of the disease investigated--in comparison to controls, while circulating immune complexes were significantly elevated only in patients in the advanced Stages of the disease (III and IV). The unchanged IgM level was found in all untreated RCC patients regarding the controls. Immuno- or immunochemotherapy did not affect the immunoreactive proteins (Ig and CIC) in the investigated patients, without respect to their clinical response to the applied therapy.
对肾细胞癌(RCC)患者的免疫反应性蛋白——血清免疫球蛋白和免疫复合物进行了评估。分析在根治性肾切除术后进行,分别于治疗前、治疗结束时以及治疗后六个月进行,单独使用干扰素α(II期患者)或干扰素α联合长春花碱(疾病III期和IV期患者)。免疫治疗或免疫化疗前获得的数据显示,在所研究的疾病各阶段的RCC患者中,IgG和IgA浓度均显著升高——与对照组相比,而循环免疫复合物仅在疾病晚期(III期和IV期)患者中显著升高。与对照组相比,所有未经治疗的RCC患者的IgM水平均未改变。免疫治疗或免疫化疗对所研究患者的免疫反应性蛋白(Ig和CIC)没有影响,无论他们对所应用治疗的临床反应如何。